Related Research Articles
The Takeda Pharmaceutical Company Limited[takeꜜda jakɯçiŋ koꜜːɡʲoː] is a Japanese multinational pharmaceutical company, with American and British roots. It is the largest pharmaceutical company in Asia and one of the top 20 largest pharmaceutical companies in the world by revenue. The company has over 49,578 employees worldwide and achieved US $19.299 billion in revenue during the 2018 fiscal year. The company is focused on metabolic disorders, gastroenterology, neurology, inflammation, as well as oncology through its independent subsidiary, Takeda Oncology. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo. In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States. As of 2015, Christophe Weber was appointed as the CEO and President of Takeda.
Gilead Sciences, Inc., is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi. Gilead is a member of the NASDAQ Biotechnology Index and the S&P 500.
Pharming, a portmanteau of "farming" and "pharmaceutical", refers to the use of genetic engineering to insert genes that code for useful pharmaceuticals into host animals or plants that would otherwise not express those genes, thus creating a genetically modified organism (GMO). Pharming is also known as molecular farming, molecular pharming or biopharming.
Biocon Limited is an Indian biopharmaceutical company that is based in Bangalore, India founded by Kiran Mazumdar-Shaw. The company manufactures generic active pharmaceutical ingredients (APIs) that are sold in over 120 countries across the globe, including the developed markets of the United States and Europe. It also manufactures novel biologics, as well as, biosimilar insulins and antibodies, which are sold in India as branded formulations. Biocon's biosimilar products are also sold in both bulk and formulation forms in several emerging markets. In contract research services, Syngene International Limited (Syngene), a publicly listed subsidiary of Biocon.
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry. It maintains headquarters in South Boston, Massachusetts, and three research facilities, in San Diego, California, and Milton Park, near Oxford, England.
A biopharmaceutical, also known as a biologic(al) medical product, or biologic, is any pharmaceutical drug product manufactured in, extracted from, or semisynthesized from biological sources. Different from totally synthesized pharmaceuticals, they include vaccines, whole blood, blood components, allergenics, somatic cells, gene therapies, tissues, recombinant therapeutic protein, and living medicines used in cell therapy. Biologics can be composed of sugars, proteins, nucleic acids, or complex combinations of these substances, or may be living cells or tissues. They are isolated from living sources—human, animal, plant, fungal, or microbial. They can be used in both human and animal medicine.
Genome Valley is an Indian high-technology business district spread across 25 km2 in Hyderabad, India. It is located across the suburbs, Turakapally, Shamirpet, Medchal, Uppal, Patancheru, Jeedimetla, Gachibowli and Keesara, the Valley has developed as a cluster for Biomedical research, training and manufacturing.
Cephalon, Inc. was an American biopharmaceutical company co-founded in 1987 by pharmacologist Frank Baldino, Jr., neuroscientist Michael Lewis, and organic chemist James C. Kauer—all three former scientists with the DuPont Company. Baldino served as Cephalon's chairman and chief executive officer, until his death in December 2010. The company's name comes from the adjective "cephalic" meaning "related to the head or brain", as it was established primarily to pursue treatments for neurodegenerative diseases.
Maxygen Inc. was a biopharmaceutical company focused on developing improved versions of protein drugs using DNA shuffling and other protein modification technologies. The company was headquartered in Redwood City, CA. It dissolved in 2013. The Maxygen legacy was revived in 2018 with a focus on Directed Evolution of Proteins using Molecular Breeding. Maxygen LLC is currently headquartered in Sunnyvale, CA.
The Virtual College of Biotechnology was formed at the beginning of 2000 and dissolved June 30, 2008. The Virtual College used an interdisciplinary approach applying courses from several colleges which would unite to benefit a researcher in the field of biotechnology.
The Ohio bioscience sector strength was ranked #4 among USA states in 2008 by Business Facilities magazine.
United Therapeutics Corporation is an American publicly traded biotechnology company listed on the NASDAQ under the symbol UTHR. Its mission is to develop novel, life-extending technologies for patients in the areas of lung disease and organ manufacturing. United Therapeutics is co-headquartered in Silver Spring, Maryland and Research Triangle Park, North Carolina, with additional facilities in Magog and Bromont, Quebec; Melbourne and Jacksonville Florida; La Jolla, California; and Manchester, New Hampshire.
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Two River Group Holdings is a New York-based venture capital firm and merchant bank focused on the life science sector. It specializes in investments in life science, biotechnology, and in firms focused on developing preventive and therapeutic technologies for a broad spectrum of disease areas including oncology, cardiovascular disease, neurological disorders, and companion animal health care.
Ambit was an American pharmaceutical company focused on development of kinase inhibitor therapeutics to treat a variety of human diseases. As of March 2014, the company was based in San Diego, California, and consisted of a single facility. Ambit made an initial public offering in May 2013 and was listed on the NASDAQ exchange under the symbol "AMBI". Ambit was acquired by Daiichi Sankyo in 2014 and is no longer traded on the NASDAQ exchange.
Henri A. Termeer was a Dutch biotechnology executive and entrepreneur who is considered a pioneer in corporate strategy in the biotechnology industry for his tenure as CEO at Genzyme. Termeer created a business model adopted by many others in the biotech industry by garnering steep prices— mainly from insurers and government payers— for therapies for rare genetic disorders known as orphan diseases that mainly affect children. Genzyme uses biological processes to manufacture drugs that are not easily copied by generic-drug makers. The drugs are also protected by orphan drug acts in various countries which provides extensive protection from competition and ensures coverage by publicly funded insurers. As CEO of Genzyme from 1981 to 2011, he developed corporate strategies for growth including optimizing institutional embeddedness nurturing vast networks of influential groups and clusters: doctors, private equity, patient-groups, insurance, healthcare umbrella organizations, state and local government, alumni. Termeer is "connected to 311 board members in 17 different organizations across 20 different industries" He has the legacy of being the "longest-serving CEO in the biotechnology industry.
Ionis Pharmaceuticals is a biotechnology company based in Carlsbad, California that specializes in discovering and developing RNA-targeted therapeutics. The company has 3 commercially approved medicines: Spinraza (Nusinersen), Tegsedi (Inotersen), and Waylivra (Volanesorsen) and has 4 drugs in pivotal studies: tominersen for Huntington’s disease, tofersen for SOD1-ALS, AKCEA-APO(a)-LRx for cardiovascular disease, and AKCEA-TTR-LRx for all forms of TTR amyloidosis.
Fortress Biotech Inc., commonly known as Fortress Bio, is a biopharmaceutical company that acquires, develops, and commercializes innovative pharmaceutical and biotechnology products. Led by CEO Lindsay A. Rosenwald, M.D., Fortress and most of its subsidiary companies are headquartered in New York City, U.S..
William H. Rastetter, a scientist, entrepreneur and venture capitalist, is the chair of Neurocrine Biosciences, of Fate Therapeutics, and of Daré Bioscience, Inc. in San Diego, California. He is a founding board member and investor in GRAIL, Inc. in Menlo Park, California, and served for a period as the company’s interim CEO (2017) and chair (2017-2018). Rastetter is also a director of Regulus Therapeutics. He was a partner in the venture firm Venrock (2006-2013), and a trustee at Caltech (2015-2018). He has served as a director (1998-2016) and as chair of Illumina (2005-2016). He advised SVB Leerink (2014-2019) and currently advises Illumina Ventures.
References
- 1 2 "Pacgen Biopharmaceuticals Acquires IL Therapeutics Inc" (PDF) (Press release). Pacgen Biopharmaceuticals. April 12, 2006. Archived from the original (PDF) on July 15, 2011. Retrieved August 11, 2018.
- ↑ "Pacgen Biopharmaceuticals Acquires IL Therapeutics Inc". Pacgen Biopharmaceuticals. April 12, 2006. Retrieved August 11, 2018.
- ↑ Saskatchewan Research Council 2005-2006 Annual Report. Sustainable Science Solutions. pp. 7–8. Archived from the original on July 6, 2011. Retrieved August 11, 2018.
- ↑ U of S News Releases: University Communication, U of S News Releases: U of S Signs Letter of Intent to Commercialize Treatment for Lung Injury Complications, archived from the original on 2011-07-06, retrieved Sep 9, 2007
- ↑ "U of S News Releases: U of S Spin-off gets $3 Million Boost to Develop Anti-inflammatory Drug" (PDF). Business View. Saskatoon and District Chamber of Commerce: 3. December 2004. Retrieved August 11, 2018.